Time filter

Source Type

EINDHOVEN, Netherlands

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: AAT.2013.4-4.;AAT.2013.1-2. | Award Amount: 3.78M | Year: 2013

A composite aero-structure with self-repair capabilities will offer durability, extend its service life and prolong maintenance protocols leading to lower aircraft operational costs. Despite the extensive research activities in the area of self-healing resins applied to composite materials, the research for aeronautical applications is currently very limited. To this end, the main objective of HIPOCRATES is the development of self-repair composite materials by transforming widely used resins within aeronautical industry to self-healing materials, facilitating this way the subsequent certification and its related cost. Taking into account the current technological maturity of self-repair, secondary structural composites shall be targeted. The transformation will be done through the epoxy enrichment with appropriate chemical agents, following three main strategies: a) The nano-encapsulation strategy that involves incorporation of nano-encapsulated healing agents and a dispersed catalyst within a polymer matrix, b) The reversible polymers strategy where remediable polymer matrices follow the Diels-Alder chemical reaction rendering damage repairable through triggered reversible cross-linking. c) A combination for the first time of a) and b). For all strategies the current progress of nano-technology will be utilized towards either better facilitation of self-healing process (e.g. nano-carriers) or enhancement of the self-healing performance or integration of other functionalities (e.g. monitoring of the self-healing performance, activation of DA reaction). Impact, fracture and fatigue mechanical tests are envisioned to assess the self-healing efficiency. Manufacturing challenges that arise from incorporating such self-healing thermosetting systems into fibrous composites (pre-preg, infusion/RTM) shall be closely investigated at the early stages of development to ensure the effective transfer of the desired properties to the large scale as required by the industry.

Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.59M | Year: 2013

The production of the next generation of functional soft systems and materials capable of meeting the current and future demands of society in a sustainable manner will require both new technologies and highly trained scientists. Supramolecular chemistry provides a powerful approach to develop new self-assembled materials with emerging properties, such as healability, recyclability and facile processability. The SASSYPOL ITN will train the next generation of European scientists with the skills necessary to overcome such future demands and simultaneously develop new strategies for the preparation of hierarchically self-assembled polymeric soft systems, which greatly impact important fields such as biomedicine, energy, composite materials and sensing. The ITN unites many leading experts in the areas of supramolecular and polymer chemistry with partners from the industrial sector. Expertise of all partners encompasses the general areas of non-covalent chemistry, with individual research competencies focusing on a number of specific themes including liquid crystalline materials, hydrogen-bonded supramolecules, molecular systems based on host-guest interactions, and advanced modeling and characterisation techniques of complex polymeric and self-assembled materials. The complementarity and diversity realised in synthesis, analysis, and applications is crucial for successful research and training in this area. A number of partners from the private sector will extend the fellows training beyond that of traditional academic settings they will have the critical role of bridging fundamental science with application and commercialisation of the results. Indeed, SupraPolix (a SME), one of SASSYPOLs industrial full partners is a perfect example of the commercialisation of cutting-edge science initially developed at an academic laboratory. Our activities will thus possess both breadth and quality that can only be achieved through an interdisciplinary pan-European effort.

Suprapolix B.V. | Date: 2009-06-23

UNPROCESSED PLASTICS, NAMELY, POLYMERS FOR ADHESIVE, COATING AND COSMETIC FORMULATIONS. PLASTICS IN EXTRUDED FORM FOR GENERAL INDUSTRIAL USE, AND PLASTIC PRODUCTS INCLUDED IN THE CLASS, NAMELY, plastic film for industrial and commercial packing use, plastic packing for shipping containers, plastic tape for use in packaging materials.

Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: NMP.2013.2.2-1 | Award Amount: 7.34M | Year: 2014

In situ tissue engineering using a biodegradable synthetic scaffold that recruits endogenous cells from the bloodstream is emerging as a promising technology to create living heart valves inside the human body having the potential to last a life-time: one valve for life. Compared to classical tissue engineered heart valves this new technology demonstrates off-the-shelf availability at substantially reduced cost. The current proposal aims to further develop the synthetic biomaterials needed for the in situ tissue engineering of heart valves, to process these materials into a functional heart valve scaffold, and to perform all the necessary pre-clinical experiments to enable first-in-man clinical application. A novel approach to the biodegradable scaffold will be developed, that combines a relatively slowly degrading (months) elastomeric material with a fast degrading (weeks) bioactive hydrogel material. These materials will be processed into a fibrous heart valve scaffold by means of electrospinning. The elastomeric material ensure long term functionality of the valve while supporting in-vivo mature tissue formation, while the fast eroding hydrogel material controls the early inflammatory response and creates the necessary void space between the elastomeric fibers. A minimally invasive, transapical, implantation technique will be used for the placement of the heart valve scaffold at the aortic position, following our recent results. For this purpose, tailor-made stents will be developed.

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.2.2-1 | Award Amount: 5.92M | Year: 2013

BIP-UPy addresses the need for biomedical implants which can be easily fine-tuned in their properties in regards to bioactivity, biodegradability, and mechanical performance, and thereby be optimized for their targeted clinical application. This project will develop a library comprising of a selection of synthetic polymers and specific bioactivities which can be used to provide the required properties for a targeted biomedical implant. The polymeric materials that will be addressed are supramolecular UPy-modified polymers for uses in urologic implants and embolic implants, benefitting large population groups: bio-degradable meshes with improved in-situ tissue regeneration in pelvic floor repair and endovascular embolic implants with a reduced aneurysm recurrence risk. A mix-and-match approach will be used to bioactivate these supramolecular base materials. The supramolecular nature of the materials allows for mild processing conditions. Main objective is to develop a methodology for obtaining implantable polymers with specifically designed bioactivity for in-situ Tissue Engineering, in which the medical implant is obtained in one step by co-processing of the peptide molecules with the neat polymeric material. Key deliverables are protocols for processable biocompatible UPy-based polymers synthesis and manufacturing scale-up; protocols for UPy-based polymers bioactivity tailoring; procedures for processing the UPy-based polymers preserving the bioactivity efficiency; sterilisation protocols for bioactive medical implants; bioactive implants prototypes with tailored bioactivities; material and implant biocompatibility and bioactivity tests data; new predictive in-vitro tests and drafts of regulatory docs. BIP-UPy consortium comprises 9 partners from 5 European countries: 3 RTD performing institutions and 2 Hospitals, 3 SMEs and 1 LE representing the strong industrial involvement. Forth SME (CHEMPILOTS-DK) has whithdrawn from project on 31/12/2014.

Discover hidden collaborations